New drug access for rare Tumor-Induced low blood sugar
NCT ID NCT07262970
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides an investigational drug, ersodetug, to people with dangerously low blood sugar caused by certain tumors. It is for those who cannot join a formal clinical trial. The goal is to help control blood sugar levels when standard treatments are not enough.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR-ASSOCIATED HYPERINSULINISM (TUMOR HI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.